Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

MYLAN INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 08:20pm CEST

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.


© PRNewswire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
05/24MYLAN NV : Free Daily Technical Summary Reports on Mylan and Three Other Generic..
AC
05/18GSK bets on lift from new lung drugs ahead of Advair's last gasp
RE
05/16Evolus investors frown as FDA declines to approve Botox rival
RE
05/14MYLAN : and West Virginia University Join Forces to Inspire West Virginia Youth ..
PR
05/10In Europe, Mylan's rivals try to plug EpiPen shortages
RE
05/09MYLAN : May Be Gem in Rough Generic Sector
DJ
05/09MYLAN : Statement on Supply of EpiPen® (epinephrine injection, USP) Auto-Injecto..
PU
05/09MYLAN : Reports First Quarter 2018 Results and Reaffirms 2018 Guidance
PR
05/02MYLAN : to Release First Quarter 2018 Financial Results on May 9, 2018
PR
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
More news
News from SeekingAlpha
2015Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript 
2015Mylan Q4 revenues up 15%, Specialty up 38% 
2015Mylan (MYL) Q4 2014 Results - Earnings Call Webcast 
2015Mylan EPS in-line, beats on revenue 
2015Notable earnings after Monday?s close